

Metadata of the article that will be visualized in OnlineFirst

1	Article Title	The ecto-enzymes CD73 and adenosine deaminase modulate 5'-AMP-derived adenosine in myofibroblasts of the rat small intestine	
2	Article Sub- Title		
3	Article Copyright - Year	Springer Nature B.V. 2018 (This will be the copyright line in the final PDF)	
4	Journal Name	Purinergic Signalling	
5	Corresponding Author	Family Name	Giron
6		Particle	
7		Given Name	Maria Cecilia
8		Suffix	
9		Organization	University of Padova
10		Division	Department of Pharmaceutical and Pharmacological Sciences
11		Address	Largo Meneghetti, 2 -, Padova 35131, Italy
12		e-mail	cecilia.giron@gmail.com
13		Author	Family Name
14	Particle		
15	Given Name		Anna
16	Suffix		
17	Organization		University of Padova
18	Division		Department of Pharmaceutical and Pharmacological Sciences
19	Address		Largo Meneghetti, 2 -, Padova 35131, Italy
20	e-mail		
21	Author		Family Name
22		Particle	
23		Given Name	Valentina
24		Suffix	
25		Organization	University of Padova
26		Division	Department of Pharmaceutical and Pharmacological Sciences
27		Address	Largo Meneghetti, 2 -, Padova 35131, Italy
28		Organization	University College Cork, Ireland and San Camillo Hospital

29		Division	APC Microbiome Ireland
30		Address	Treviso, Italy
31		e-mail	
32		Family Name	Bistoletti
33		Particle	
34		Given Name	Michela
35	Author	Suffix	
36		Organization	University of Insubria
37		Division	Department of Medicine and Surgery
38		Address	Varese, Italy
39		e-mail	
40		Family Name	Montopoli
41		Particle	
42		Given Name	Monica
43	Author	Suffix	
44		Organization	University of Padova
45		Division	Department of Pharmaceutical and Pharmacological Sciences
46		Address	Largo Meneghetti, 2 -, Padova 35131, Italy
47		e-mail	
48		Family Name	Colucci
49		Particle	
50		Given Name	Rocchina
51	Author	Suffix	
52		Organization	University of Padova
53		Division	Department of Pharmaceutical and Pharmacological Sciences
54		Address	Largo Meneghetti, 2 -, Padova 35131, Italy
55		e-mail	
56		Family Name	Antonioli
57		Particle	
58		Given Name	Luca
59	Author	Suffix	
60		Organization	University of Pisa
61		Division	Department of Clinical and Experimental Medicine
62		Address	Via Roma 55, Pisa 56126, Italy
63		e-mail	
64	Author	Family Name	Martin

65		Particle	De
66		Given Name	Sara
67		Suffix	
68		Organization	University of Padova
69		Division	Department of Pharmaceutical and Pharmacological Sciences
70		Address	Largo Meneghetti, 2 -, Padova 35131, Italy
71		e-mail	
72		Family Name	Castagliuolo
73		Particle	
74		Given Name	Ignazio
75		Suffix	
76	Author	Organization	University of Padova
77		Division	Department of Molecular Medicine
78		Address	via Gabelli, 63 -, Padova 35121, Italy
79		e-mail	
80		Family Name	Orso
81		Particle	
82		Given Name	Genny
83		Suffix	
84		Organization	University of Padova
85	Author	Division	Department of Pharmaceutical and Pharmacological Sciences
86		Address	Largo Meneghetti, 2 -, Padova 35131, Italy
87		Organization	IRCCS "E. Medea" Bosisio Parini
88		Division	
89		Address	Lecco, Italy
90		e-mail	
91		Family Name	Giaroni
92		Particle	
93		Given Name	Cristina
94		Suffix	
95	Author	Organization	IRCCS "E. Medea" Bosisio Parini
96		Division	
97		Address	Lecco, Italy
98		e-mail	
99	Author	Family Name	Debetto
100		Particle	

101	Given Name	Patrizia
102	Suffix	
103	Organization	University of Padova
104	Division	Department of Pharmaceutical and Pharmacological Sciences
105	Address	Largo Meneghetti, 2 -, Padova 35131, Italy
106	e-mail	
107	Received	20 October 2017
108	Schedule Revised	
109	Accepted	21 August 2018
110	Abstract	Adenosine is a versatile signaling molecule recognized to physiologically influence gut motor functions. Both the duration and magnitude of adenosine signaling in enteric neuromuscular function depend on its availability, which is regulated by the ecto-enzymes ecto-5'-nucleotidase (CD73), alkaline phosphatase (AP), and ecto-adenosine deaminase (ADA) and by dipyridamole-sensitive equilibrative transporters (ENTs). Our purpose was to assess the involvement of CD73, APs, ecto-ADA in the formation of AMP-derived adenosine in primary cultures of ileal myofibroblasts (IMFs). IMFs were isolated from rat ileum longitudinal muscle segments by means of primary explant technique and identified by immunofluorescence staining for vimentin and α -smooth muscle actin. IMFs confluent monolayers were exposed to exogenous 5'-AMP in the presence or absence of CD73, APs, ecto-ADA, or ENTs inhibitors. The formation of adenosine and its metabolites in the IMFs medium was monitored by high-performance liquid chromatography. The distribution of CD73 and ADA in IMFs was detected by confocal immunocytochemistry and qRT-PCR. Exogenous 5'-AMP was rapidly cleared being almost undetectable after 60-min incubation, while adenosine levels significantly increased. Treatment of IMFs with CD73 inhibitors markedly reduced 5'-AMP clearance whereas ADA blockade or inhibition of both ADA and ENTs prevented adenosine catabolism. By contrast, inhibition of APs did not affect 5'-AMP metabolism. Immunofluorescence staining and qRT-PCR analysis confirmed the expression of CD73 and ADA in IMFs. Overall, our data show that in IMFs, an extracellular AMP-adenosine pathway is functionally active and among the different enzymatic pathways regulating extracellular adenosine levels, CD73 and ecto-ADA represent the critical catabolic pathway.
111	Keywords separated by ' - '	Intestine - Adenosine - CD73/ecto-5' nucleotidase - Adenosine deaminase - Alkaline phosphatase - Adenosine receptor - Rat - Myofibroblasts
112	Foot note information	Anna Bin and Valentina Caputi contributed equally to this work.

The ecto-enzymes CD73 and adenosine deaminase modulate 5'-AMP-derived adenosine in myofibroblasts of the rat small intestine

Anna Bin¹ · Valentina Caputi^{1,2} · Michela Bistoletti³ · Monica Montopoli¹ · Rocchina Colucci¹ · Luca Antonioli⁴ · Sara De Martin¹ · Ignazio Castagliuolo⁵ · Genny Orso^{1,6} · Cristina Giaroni⁶ · Patrizia Debetto¹ · Maria Cecilia Giron¹

Received: 20 October 2017 / Accepted: 21 August 2018
© Springer Nature B.V. 2018

Abstract

Adenosine is a versatile signaling molecule recognized to physiologically influence gut motor functions. Both the duration and magnitude of adenosine signaling in enteric neuromuscular function depend on its availability, which is regulated by the ecto-enzymes ecto-5'-nucleotidase (CD73), alkaline phosphatase (AP), and ecto-adenosine deaminase (ADA) and by dipyridamole-sensitive equilibrative transporters (ENTs). Our purpose was to assess the involvement of CD73, APs, ecto-ADA in the formation of AMP-derived adenosine in primary cultures of ileal myofibroblasts (IMFs). IMFs were isolated from rat ileum longitudinal muscle segments by means of primary explant technique and identified by immunofluorescence staining for vimentin and α -smooth muscle actin. IMFs confluent monolayers were exposed to exogenous 5'-AMP in the presence or absence of CD73, APs, ecto-ADA, or ENTs inhibitors. The formation of adenosine and its metabolites in the IMFs medium was monitored by high-performance liquid chromatography. The distribution of CD73 and ADA in IMFs was detected by confocal immunocytochemistry and qRT-PCR. Exogenous 5'-AMP was rapidly cleared being almost undetectable after 60-min incubation, while adenosine levels significantly increased. Treatment of IMFs with CD73 inhibitors markedly reduced 5'-AMP clearance whereas ADA blockade or inhibition of both ADA and ENTs prevented adenosine catabolism. By contrast, inhibition of APs did not affect 5'-AMP metabolism. Immunofluorescence staining and qRT-PCR analysis confirmed the expression of CD73 and ADA in IMFs. Overall, our data show that in IMFs, an extracellular AMP-adenosine pathway is functionally active and among the different enzymatic pathways regulating extracellular adenosine levels, CD73 and ecto-ADA represent the critical catabolic pathway.

Keywords Intestine · Adenosine · CD73/ecto-5'-nucleotidase · Adenosine deaminase · Alkaline phosphatase · Adenosine receptor · Rat · Myofibroblasts

Anna Bin and Valentina Caputi contributed equally to this work.

✉ Maria Cecilia Giron
cecilia.giron@unipd.it



- ¹ Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo Meneghetti, 2 -, 35131 Padova, Italy
- ² APC Microbiome Ireland, University College Cork, Ireland and San Camillo Hospital, Treviso, Italy
- ³ Department of Medicine and Surgery, University of Insubria, Varese, Italy
- ⁴ Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
- ⁵ Department of Molecular Medicine, University of Padova, via Gabelli, 63 -, 35121 Padova, Italy
- ⁶ IRCCS "E. Medea" Bosisio Parini, Lecco, Italy

Abbreviations

ADA	Adenosine deaminase	30
AOPCP	α,β -methyleneadenosine 5'-diphosphate sodium salt	34
CD73	ecto-5'-nucleotidase	38
EHNA	Erythro-9-(2-hydroxy-3-nonyl) adenine	30
ENTs	Equilibrative transporters	42
HPLC	High-pressure liquid chromatography	43
IMFs	Ileal myofibroblasts	46
AP	Alkaline phosphatase	48
PAP	Prostatic acid phosphatase	50

Introduction

Adenosine is considered an important signaling molecule involved in the modulation of gastrointestinal motor, secretory/

55	absorptive, and immune responses. This nucleoside exerts its	culture of myofibroblasts are still unknown. Thus, the purpose	108
56	effects through four G protein-coupled P1 purinergic recep-	of the present study was to assess the physiological role of the	109
57	tors, namely A ₁ , A _{2A} , A _{2B} , and A ₃ receptors, located on the	ecto-enzymes CD73 and ecto-ADA in modulating extracellu-	110
58	surface of diverse enteric cells such as neuronal, glial, epithe-	lar adenosine levels in primary culture of rat ileal myofibro-	111
59	lial, smooth muscle, and immune cells [1, 2]. Each P1 receptor	blasts (IMFs).	112
60	subtype is characterized by distinct binding affinities for adeno-		
61	sine as well as by diverse expression and functional profile		
62	along the gastrointestinal tract in both physiological and path-		
63	ological conditions [3–6].		
64	Adenosine levels in interstitial fluids are dependent on the	Materials and methods	113
65	combined actions of several processes, including cellular re-		
66	lease and re-uptake, extracellular and intracellular metabolism	Animals and tissue preparation	114
67	[7–11]. In pathological conditions, such as hypoxia or inflam-		
68	mation, extracellular adenosine levels considerably raise,	Male Wistar rats (250 ± 50 g body weight; Harlan, Italy) were	115
69	playing a pivotal role in the regulation of neuromuscular and	housed at the conventional animal facility of the Department	116
70	inflammatory responses [3–5, 12]. The major process respon-	of Pharmaceutical and Pharmacological Sciences of the	117
71	sible for the rapid extracellular adenosine increase following a	University of Padova under temperature and humidity-	118
72	harmful insult is represented by ATP and ADP dephosphory-	controlled conditions with ad libitum access to standard labo-	119
73	lation, which are transformed into 5'-AMP (AMP) by the ecto-	ratory chow and tap water, and a regular 12/12-h light/dark	120
74	nucleoside triphosphate diphosphohydrolase 1 (CD39). AMP	cycle. All experimental protocols were approved by the	121
75	is successively dephosphorylated to adenosine by the ecto-5'-	Animal Care and Use Committee of the University of	122
76	nucleotidase (CD73) and/or by the alkaline phosphatases	Padova and by the Italian Ministry of Health and were in	123
77	(APs) [13–15].	compliance with the national and EU guidelines for handling	124
78	In physiological conditions, a more amendable source of	and use of experimental animals. Immediately after decapita-	125
79	extracellular adenosine is represented by cyclic adenosine	tion, segments of ileum were excised, deprived of the mesen-	126
80	monophosphate (cAMP), which, once extruded from activat-	tery and related tissues, and placed in ice-cold phosphate-buff-	127
81	ed cells, can be converted into AMP and then to adenosine by	ered saline (PBS), supplemented with 0.25 µg/mL	128
82	ecto-phosphodiesterase and by CD73, respectively [16]. In	amphotericin B and 20 µg/mL gentamicin, and aerated with	129
83	this regard, considering the findings of Nitahara et al. in iso-	95% O ₂ /5% CO ₂ [10].	130
84	lated longitudinal muscle strips of guinea pig ileum [7], we		
85	were the first to reveal CD73 expression in rat ileum	Cultures of ileal myofibroblasts	131
86	muscularis externa and in primary culture of ileal smooth		
87	muscle cells and to highlight the critical role of CD73 in the	IMFs were explanted from the muscularis externa of the rat	132
88	formation of extracellular adenosine at both levels [10].	ileum, as previously reported [10]. Briefly, isolated longitudi-	133
89	Intriguingly, in rat ileal longitudinal muscle-myenteric prepa-	nal smooth muscle strips were collectively minced and cul-	134
90	rations (LMMPs), Duarte-Araújo et al. [8] and Correia-de-Sà	tured in DMEM (Cambrex, Italy) supplemented with 20%	135
91	et al. [9] have shown that extracellular AMP-derived adeno-	fetal bovine serum (FBS, Celbio, Pero, Italy), 20 µg/mL gen-	136
92	sine by interacting with pre-junctional A _{2A} facilitatory recep-	tamicin, 2 mM L-glutamine, and 0.1 mM MEM Eagle NEAA	137
93	tors (but not with A ₁ inhibitory receptors) evoked an increase	and maintained at 37 °C in a humidified 5% CO ₂ atmosphere.	138
94	in the release of acetylcholine from electrically stimulated	On reaching confluence, explants were dissociated using	139
95	myenteric neurons.	0.125% (wt/vol) trypsin and EDTA*4Na (0.38 g/L) in	140
96	The effect of both adenosine and AMP is interrupted by	Hanks' balanced salt solution (HBBS) for 1 min at 37 °C.	141
97	equilibrative nucleoside transporters (ENTs) and/or by ecto-	Isolated cells were then seeded onto 60-mm dishes at a density	142
98	adenosine deaminase (ecto-ADA), a ubiquitous catabolic en-	of 3 × 10 ⁵ cells/mL and maintained in DMEM containing	143
99	zyme localized on cell surfaces, which reduces adenosine ex-	10% FBS. All experiments were performed on almost confluent	144
100	tracellular levels in the biophase of its receptors [17]. Of note,	cultures (3 × 10 ⁵ per well), for no more than two passages	145
101	ecto-ADA may be found either in a soluble form in interstitial	[10]. IMFs integrity and viability were determined by light	146
102	fluids or in a cell-associated form, bound to CD26 or adeno-	microscopy observations and trypan blue dye exclusion assay.	147
103	sine receptor [9, 15, 17–19].	After incubation with or without AMP in absence or presence	148
104	Although several studies have revealed a critical role of	of the enzyme inhibitors, cells were treated with 0.4% trypsin	149
105	CD73 in the control of extracellular adenosine levels in the	to obtain cell suspensions that were thoroughly mixed with	150
106	gut [4, 13–15, 19], the relevant enzymes involved in regulat-	equal volumes of 0.4% trypan blue solution (Gibco, Grand	151
107	ing adenosine levels at P1 receptors located on gut primary	Island, NY, USA) and incubated for 3 min at 37 °C. Live	152
		(non-stained) and dead (stained) cells were estimated using a	153
		hemocytometer according to manufacturer's instructions.	154

155 Measurement of surface enzymes activity

156 IMFs, grown to subconfluence in DMEM supplemented with
 157 10% FBS, were washed twice with PBS and incubated for
 158 24 h with 1 mL of DMEM supplemented with 0.4% FBS.
 159 AMP (50 μ M) was added to the cells in 1 ml-final volume
 160 and incubated for diverse time periods. In different experi-
 161 mental settings, IMFs were treated with 50 μ M AMP in the
 162 presence or absence of the following: (i) α , β -methyleneaden-
 163 osine-5'-diphosphate (AOPCP, 0.2 mM) [20]; (ii) concanava-
 164 lin A (ConA, 0.1 mg/mL) [21]; (iii) levamisole (10 mM) [22];
 165 (iv) erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, 10 μ M)
 166 [9, 10]; (v) dipyrindamole (0.5 μ M) added 15 min before the
 167 exogenous nucleotide. After incubation, 1-mL samples of
 168 IMFs incubation medium were collected into tubes containing
 169 HClO₄ (1 M, final concentration) and stored at - 80 °C until
 170 HPLC analysis.

171 For Eadie–Hofstee graphical analysis, incubation time was
 172 5 min to prevent substrate depletion. Product formation was
 173 expressed as μ mol/min of adenosine + inosine +
 174 hypoxanthine.

175 HPLC analysis of purines

176 Samples of IMFs incubation medium were brought to about
 177 pH 4–5 with 1 N NaOH and then mixed with 50 μ M theophyl-
 178 line as internal standard. After centrifugation (3000 g for
 179 5 min), clear supernatants were filtered through a 0.22- μ m
 180 syringe filter and analyzed by HPLC-UV (Beckman System
 181 Solvent Module 125) on a Beckman C18 Analytical
 182 Ultrasphere column, using a mobile phase consisting of
 183 73.5 mM NaH₂PO₄/6 mM tetra-n-butylammonium bromide
 184 (pH 5.8; solvent A) and methanol (solvent B), applying a non-
 185 linear gradient at a flow rate of 1 mL/min, as previously de-
 186 scribed [10]. AMP, adenosine, inosine, and hypoxanthine and
 187 ATP were detected by UV absorbance (254 nm, Beckman
 188 Detector 166) and quantified from absorbance peak area.
 189 The concentration of purines was extrapolated from calibra-
 190 tion curves. A representative chromatogram of standards mix-
 191 ture of purines (i.e., AMP, adenosine, inosine, and hypoxan-
 192 thine and ATP) and internal standard (i.e., theophylline) is
 193 depicted in Fig. 1.

194 Immunocytochemistry

195 Desmin, vimentin, alpha smooth muscle actin (α -SMA),
 196 CD73 and ADA were detected by indirect immunofluores-
 197 cence in IMFs plated in glass cover slips. Cells were fixed in
 198 4% paraformaldehyde for 15 min and incubated with 0.05 M
 199 NH₄Cl. Fixed cells were rinsed with PBS, permeabilized with
 200 0.1% Triton X-100, and incubated with the following primary
 201 antibodies: rabbit polyclonal anti-human desmin (1:100,
 202 Thermo Fisher Scientific, Milan, Italy), mouse monoclonal

anti-human vimentin (1:100, clone V9, Dako, Italy), mouse
 monoclonal α -SMA FITC-conjugated (1:200; clone 1A4,
 Sigma Aldrich, Milan, Italy), mouse anti-rat CD73 (1:500;
 BD Biosciences Pharmingen, Belgium), and biotin-labeled rab-
 bit anti-bovine ADA (1:100; Alpha Diagnostic International
 Inc., USA), diluted in PBS containing 0.1% BSA and 10%
 normal goat serum for 1 h at room temperature [10, 23, 24].


203 Thereafter, IMFs were incubated with goat anti-mouse or
 204 streptavidin labeled with Alexa Fluor 488 and with anti-rabbit
 205 labeled with Alexa Fluor 555 (1:1000; Thermo Fisher
 206 Scientific, Milano, Italy), for 1 h at room temperature. Cell
 207 nuclei were stained with 4',6-diamidino-2-phenylindole,
 208 dihydrochloride (DAPI) (1:1000; Thermo Fisher Scientific,
 209 Milan, Italy), added together with the secondary antibodies.
 210 To obtain negative controls, IMFs were also incubated with
 211 appropriate isotype-matched control antibodies or without pri-
 212 mary antibody or pre-incubated with each antibody with the
 213 corresponding control peptide (final concentration as indicat-
 214 ed by manufacturer's instructions) [10, 23]. Stained cells were
 215 imaged with a Zeiss LSM 800 confocal laser-scanning micro-
 216 scope (Carl Zeiss AG, Germany) and analyzed using NIH
 217 Image J software (version 1.50a) [23].
 218
 219
 220
 221
 222
 223
 224

RNA isolation and quantitative RT-PCR

225 Quantitative reverse transcription PCR (qRT-PCR) analysis
 226 was conducted on rat IMFs lysates obtained from three differ-
 227 ent cell cultures. To conduct each experiment, 1.2×10^6 cells
 228 were collected from each cell culture. Total RNA was extract-
 229 ed using a Quick-RNA MicroPrep (ZYR1050, Zymo Res,
 230 Euroclone, Milan, Italy) according to the manufacturer's
 231 instructions.
 232

233 Two microgram of total RNA was reverse transcribed using
 234 High Capacity cDNA Reverse Transcription (Applied
 235 Biosystems, Milan, Italy). Quantitative RT-PCR was per-
 236 formed on the Abi Prism 7000 real-time thermocyclator
 237 (Applied Biosystems, Milan, Italy) with Power Sybr Green
 238 Universal PCR Master Mix (Applied Biosystems, Milan,
 239 Italy) according to manufacturer's instructions. Primers were
 240 designed using Primer Express software (Applied Biosystems,
 241 Milan, Italy) according to the available sequences deposited in
 242 open access databases. The primer sequences are listed in
 243 Table 1. For qRT-PCR a 500-nM-final concentration for each
 244 primer was used. Primers were designed to have a similar
 245 amplicon size and similar amplification efficiency as required
 246 for the application of the Ct (cycle threshold) method as a
 247 relative measure of the concentration of target gene in our
 248 samples, where Ct represents the number of cycles required
 249 for the fluorescent signal to cross the threshold, thus exceed-
 250 ing background level [25]. β -actin was used as a housekeep-
 251 ing gene. Experiments were carried out two times for each
 252 different preparation ($n = 3$).

Fig. 1 Purines HPLC analysis. A representative chromatogram of standards mixture of purines (i.e., ATP, ADP, cAMP, AMP, adenosine, IMP, inosine, hypoxanthine, and uric acid) and internal standard (i.e., theophylline)



253 Drugs and chemicals

254 Amphotericin B, trypsin, EDTA, and gentamicin were pur-
 255 chased from Invitrogen-Gibco (Milano, Italy). Fetal bovine
 256 serum (FBS) was from Celbio (Pero, Italy). Formaldehyde
 257 (37%) and Triton X-100 were from Applichem (Milano,
 258 Italy). Tetra-n-butylammonium bromide (TBA) was from
 259 Merck (Darmstadt, Germany). Unless otherwise specified,
 260 all other chemicals were obtained from Sigma Aldrich
 261 (Milan, Italy) and were of the highest available analytical
 262 grade. Drugs were prepared as concentrated stock solutions
 263 in sterile H₂O mQ grade and diluted into DMEM or Krebs
 264 solution just before use.

265 Statistical analysis

266 All data were expressed as mean \pm SEM; *n* refers to the num-
 267 ber of animal preparations on which observations were made.
 268 Statistical analysis of data was performed by paired or

t1.1 **Table 1** Sequence of primers used for the q-RT PCR analysis of ADA and CD73 expression in IMFs and relative length of the amplification products

t1.2	Gene	Sequence 5'-3'	Length
t1.3	ADA	Fw CTGGAATCCCAAACGACGC Rev TCGTCCGAGTTGAGGGAGTA	75 bp
t1.4	CD73	Fw TGTGGGACCAGCAACTCAA Rev TTTGAGGCTCAGTGGTAGCC	136 bp
t1.5	β -actin	Fw TGACAGGATGCAGAAGGAGA Rev TAGAGCCACCAATCCACACA	104 bp


unpaired Student's *t* tests or by one-way analysis of variance (ANOVA) followed by Neuman-Keuls multicomparison test when appropriate, using Graph Pad Prism 3.03 (San Diego, CA-USA). *p* values of < 0.05 were considered statistically significant. Linear logistic regression (Pearson's correlation coefficient) and correlation analysis were performed in selected experiments.

Results

IMFs metabolize exogenous AMP

To characterize the enzyme machinery involved in controlling adenosine levels in the enteric smooth muscle layer, a primary culture of rat IMFs from rat small intestine was obtained using the tissue explant technique, without the use of enzymatic tissue dissociation. The lineage identity of IMFs was confirmed by the expression of α -SMA and vimentin and the absence of desmin immunoreactivity (Fig. 2) [24]. After 60-min incubation of IMFs in the absence of AMP the release of $0.54 \pm 0.24 \mu\text{M}$ AMP, $0.45 \pm 0.03 \mu\text{M}$ adenosine, $0.16 \pm 0.12 \mu\text{M}$ inosine, and $1.34 \pm 0.29 \mu\text{M}$ hypoxanthine was determined in the incubation medium. Following the addition of $50 \mu\text{M}$ AMP to the incubation medium a time-dependent decrease in the nucleotide concentration occurred (Fig. 3). The average half-life of exogenously added AMP was 4.1 ± 0.6 min. The disappearance of AMP from the incubation medium was associated with a time-related increase in the levels of its metabolites over basal values (Fig. 3), suggesting that

Fig. 2 Immunohistochemical characterization of rat IMFs. **a** Representative confocal microphotographs showing the distribution of vimentin (green) and desmin (red) in rat IMFs. **b** Representative confocal microphotographs showing the distribution of α -SMA (green) and desmin (red) in rat IMFs. Isotype fluorescent images were obtained by labeling with Alexa Fluor 488 and Alexa Fluor 555 conjugated secondary antibodies in presence of nonimmune rabbit or mouse antiserum instead of the primary antibodies. Cell nuclei were stained with DAPI (blue). $n = 6$. Scale bars = 25 μ m



295 these metabolites originated from AMP catabolism by IMFs
 296 enzymes. During a 60 min-incubation period, the total metabolite
 297 pool (i.e., adenosine + inosine + hypoxanthine) reached a
 298 maximum concentration in the medium after 15 min and
 299 remained steady thereafter (Fig. 3), although the time course
 300 describing the enhancement of each metabolite concentration
 301 in the medium was different. As shown in Fig. 3, adenosine
 302 concentration reached a maximum value of $27.0 \pm 1.1 \mu\text{M}$ at
 303 30 min, while inosine and hypoxanthine highest concentra-
 304 tions were $1.53 \pm 0.50 \mu\text{M}$ and $4.65 \pm 0.67 \mu\text{M}$, respectively,
 305 at 60 min. In addition, adenosine levels were already statisti-
 306 cally significant versus basal control levels at 5 min, while a
 307 60-min time period was required for inosine and hypoxanthine
 308 to rise above basal levels (Fig. 3). After 60 min, the pool of
 309 adenosine + inosine + hypoxanthine accounted for approxi-
 310 mately 61% of the amount of AMP cleared from the medium.
 311 When increasing concentrations of AMP (10–100 μM) were
 312 added to IMFs, the reduction of AMP levels (Fig. 4a) was
 313 paralleled by a proportional increase in the levels of adenosine
 314 (Fig. 4b) and its metabolites (data not shown) after 60 min-
 315 incubation period. The kinetics of AMP catabolism at increas-
 316 ing concentrations after 5-min incubation, evaluated by
 317 Eadie–Hofstee graphical technique, gave a linear plot
 318 (Fig. 4b) with a K_m value of 146 μM . These findings suggest
 319 that, in our model, adenosine production is far more depen-
 320 dent on AMP than inosine and hypoxanthine production.

321 IMFs express CD73 and adenosine deaminase

322 To further characterize the extracellular AMP-adenosine path-
 323 way in IMFs primary cultures, we evaluated the expression of
 324 the enzymes CD73 and ecto-ADA. IMFs showed positive
 325 immunoreactivity for CD73 and ecto-ADA (Fig. 5a, b), sug-
 326 gesting that these cells are potentially capable of metabolizing
 327 extracellular adenosine. qRT-PCR analysis showed that

mRNAs for both CD73 and ADA are expressed in rat IMFs,
 yielding Ct values of 21.94 ± 0.18 ($n = 3$) and 23.22 ± 0.20
 ($n = 3$), respectively (Fig. 5c). Correct length amplification
 was confirmed by running qRT-PCR products on an agarose
 gel, which showed the predicted amplification bands at 136 bp
 and 75 bp for CD73 and ADA, respectively (Fig. 5d).

334 CD73 and ADA regulate adenosine levels in IMFs

To test if the activation of ecto-ADA and CD73 and APs may
 underlie adenosine metabolism, IMFs were incubated with
 50 μM AMP in the presence of specific inhibitors for these
 ecto-enzymes. Figure 6 shows the time course of AMP catabolism
 and adenosine formation in the presence of two chemically
 distinct CD73 inhibitors, the ADP analogue, AOPCP (0.2 mM;
 Fig. 6a), and the non-nucleoside lectin, concanavalin A (ConA
 0.1 mg/mL; Fig. 6b). Both the two membrane-impermeable
 inhibitors of CD73 proportionally reduced AMP clearance and
 adenosine formation by about 60% (Fig. 6a, b). After 60-min
 incubation with AOPCP (Fig. 6a) or ConA (Fig. 6b), the
 average half-life of exogenously added AMP increased to 9.9
 min and 9.7 min, respectively. Treatment of IMFs with AMP
 in the presence of 10 mM levamisole, an APs inhibitor [22],
 did not affect the conversion of AMP to adenosine as demon-
 strated by the average half-life which remains equal to 4.1
 min (Fig. 6c). The ecto-ADA inhibitor EHNA (10 μM) did
 not influence AMP metabolism (Fig. 7a) but significantly
 increased adenosine accumulation in AMP-treated IMFs (Fig.
 7a) and markedly reduced AMP-induced inosine + hypoxan-
 thine accumulation that resulted comparable to basal levels
 ($0.22 \pm 0.08 \mu\text{M}$ inosine and $1.14 \pm 0.19 \mu\text{M}$ hypoxanthine).
 Treatment of IMFs with AMP in the presence of dipyridamole,
 an inhibitor of ENTs, did not affect the conversion of AMP to
 adenosine after 60 min of incubation (Fig. 7b). However,
 a significant increase of

Q1

Fig. 3 IMFs metabolize exogenous AMP. **a** Residual concentration of exogenous AMP and time-dependent conversion of AMP to extracellular adenosine, inosine and hypoxanthine in the medium of cultured IMFs. IMFs were incubated for the indicated times with exogenous AMP (50 μ M, $n = 6$). *, # $p < 0.05$ versus time = 0 min. **b** Representative chromatograms illustrating the changes in AMP, IMP, adenosine, inosine, hypoxanthine, and uric acid levels obtained by injecting IMFs-free supernatants collected after 0.5, 5, 15, 30, and 60 min-incubation with exogenous AMP (50 μ M) and processed for separation and quantification by reverse phase HPLC and UV absorbance detection









Fig. 4 Concentration-dependence of exogenous AMP catabolism by rat IMFs. **a** Purine metabolites (adenosine, inosine and hypoxanthine) levels in IMFs medium after 60-min incubation with AMP (10–100 μ M; $n = 6$).

b Eadie–Hofstee plot of v (μ mol/min) versus $v/[AMP]$ illustrating CD73 activity after 5-min incubation with 5–100 μ M AMP ($n = 6$)

Fig. 5 Rat IMFs express CD73 and ADA enzymes. **a** Representative confocal microphotographs showing the distribution of CD73 (green) or **b** ADA (green) in rat IMFs. Isotype fluorescent images were obtained by labelling with Alexa Fluor 488 conjugated secondary antibody in presence of nonimmune rabbit or mouse antiserum instead of the primary antibodies. Cell nuclei were stained with DAPI (blue). $n = 6$. Scale bars = 25 μm . **c** RT-PCR analysis of CD73, ADA, and of β -actin transcripts in rat IMFs. Values are expressed as number of threshold cycles (C_t) \pm SEM, $n = 3$. **d** Representative microphotograph showing qRT-PCR products on an agarose gel




361 adenosine levels was found following 60 min-incubation with
 362 both dipyridamole + EHNA (Fig. 7b), to suggest that IMFs
 363 clear adenosine primarily through adenosine deaminase but
 364 also through its uptake via ENTs to prevent long-term in-
 365 creases of extracellular adenosine, as previously observed in
 366 rat ileal longitudinal muscle—myenteric plexus preparations
 367 [8]. These results support the presence of a very intense extra-
 368 cellular CD73 activity compared to that of APs and ecto-ADA
 369 in IMFs, suggesting that CD73 is primarily responsible for
 370 rapid AMP dephosphorylation to adenosine in our model.

371 Discussion

372 In the gut, adenosine acts as an autocrine and paracrine mes-
 373 senger on most cell types [1, 4, 12]. Until now, most of the
 374 research has been devoted to understanding adenosine-
 375 signaling in the myenteric plexus; however, data concerning
 376 the physiological relevance of AMP and related ecto-enzymes
 377 CD73 and ADA in controlling adenosine levels in gut IMFs
 378 are still limited [8–10, 15, 19]. Smooth muscle myopathies
 379 have been observed in various gastrointestinal diseases,

including chronic intestinal pseudo-obstruction (CIP) [26] 380
 and inflammatory bowel disease (IBD) [27–29]. IMFs show 381
 morphologic and functional features of both fibroblasts and 382
 smooth muscle cells and appear to transdifferentiate from 383
 these cells or to originate from primitive stem cells. Even if 384
 IMFs exact function, content and involvement are still to be 385
 defined, they play an important role in intestinal injury, in- 386
 flammation, fibrosis, and tissue repair [30]. In Crohn's disease 387
 (CD), ileal strictures are associated to increased intestinal ob- 388
 struction, often resulting in surgical intervention, and usually 389
 developed from a chronic transmural inflammation that elicits 390
 an exaggerated deposition of extracellular matrix released by 391
 activated IMFs. Of note, in CD, a constant process of differ- 392
 entiation and de-differentiation between the three mesenchy- 393
 mal phenotypes (i.e., fibroblasts, smooth muscle cells, and 394
 IMFs) has been detected with a prevalent phenotypic switch 395
 of fibroblasts into IMFs [30]. During CD, also interstitial cells 396
 of Cajal (ICC), another type of myofibroblasts involved in the 397
 propagation of electrical events, have been shown to almost 398
 completely disappear within both muscle layers or to be 399
 destroyed during fibrosis and replaced by fibroblasts [31]. 400
 Thus, a detailed characterization of the enzymatic pathways 401

Fig. 6 Influence of alkaline phosphatase and CD73 inhibitors on AMP levels and adenosine accumulation in IMFs incubation medium. IMFs were incubated with AMP (50 μ M) for 60 min in presence or absence of AOPCP (0.2 mM; $n = 6$; **a**), or ConA (0.1 mg/ml; $n = 6$; **b**), or levamisole (10 mM; $n = 6$; **c**). * $p < 0.05$ versus AMP; # $p < 0.05$ versus adenosine




402 that modulate extracellular adenosine levels may be useful for
403 defining potential therapies [32].

404 Adenosine production can take place both in the intracel-
405 lular and extracellular compartments. The intracellular path-
406 way comprises the constitutive transmethylation pathway in-
407 volving the cleavage of S-adenosyl-L-homocysteine (SAH) to
408 L-homocysteine and adenosine by the SAH hydrolase, and the
409 enzymatic ATP dephosphorylation into adenosine by cytosolic
410 nucleotidase when energy supply fails to meet cellular en-
411 ergy demand [32, 33]. Once produced, adenosine can be ex-
412 truded through the cell membrane via facilitated diffusion nu-
413 cleoside transporters to interact with its G protein-coupled
414 receptors. The extracellular ATP-adenosine pathway involves

415 adenine nucleotides released by several cell populations and
416 then metabolized to adenosine by different ecto-enzymes such
417 as ecto-ATPase, ecto-ADPase and CD73 [12]. The postsynap-
418 tic localization of CD73 was firstly shown by immunohisto-
419 chemistry combined with electron microscopy in the guinea
420 pig ileum [7]. Upon release, adenosine can then activate adeno-
421 sine P1 receptors or can be internalized through equilibrative
422 or concentrative transporters, representing a recognized re-
423 uptake system involved in the control of the nucleoside extra-
424 cellular levels at the myenteric neuromuscular junction [8, 9].
425 In rat ileum preparations of LMMPs, Duarte-Araújo et al. [8]
426 and Correia-de-Sá et al. [9] demonstrated that the adenosine,
427 generated from exogenous AMP in the extracellular milieu,

Fig. 7 Effects of ecto-ADA and ENTs inhibition on AMP levels and adenosine accumulation in IMFs incubation medium. IMFs were incubated with AMP (50 μ M) for 60 min in presence or absence of EHNA (1 μ M; $n = 4$), dipyridamole (0.5 μ M; $n = 4$), or EHNA + dipyridamole ($n = 4$). * $p < 0.05$ versus adenosine in absence of the inhibitors



428 interacts with pre-junctional facilitatory A_{2A} adenosine receptors (but not with A_1 inhibitory receptors) and determines the
 429 release of acetylcholine from electrically activated myenteric neurons. The cAMP-adenosine pathway has also been put
 430 forward as a more suitable mechanism underlying the hormonal modulation of adenosine levels at the cell surface,
 431 where adenosine receptors are located [16]. In this respect,
 432 we have provided substantial evidence for a physiological role played by the extracellular cAMP-adenosine pathway in the
 433 small intestine [10].

438 Our study provides demonstration that IMFs express CD73, which retains a physiological role in modulating adenosine
 439 generation in the gut neuromuscular layer [7]. Furthermore, we show that AMP is metabolized to adenosine
 440 by CD73 and the nucleoside is subsequently deaminated into inosine by ecto-ADA; both are key enzymes involved in controlling
 441 adenosine levels in IMFs. In our experiments, a progressive and rapid decrease of exogenously added AMP was found in
 442 IMFs medium, with a $t_{1/2}$ of about 4 min. This clearance was paralleled by a rapid accumulation of AMP-derived
 443 metabolites, namely, adenosine, inosine, and hypoxanthine. In particular, 15 min after AMP addition to the medium, adenosine
 444 levels reached a steady state while no changes in inosine
 445
 446
 447
 448
 449
 450

451 levels were detected at end of the 60-min incubation period. CD73 is claimed to be the rate limiting enzyme of adenosine
 452 generation from the extracellular catabolism of adenine nucleotides catalyzed by the ectonucleotidase cascade, which, in the
 453 myenteric neuromuscular junction of the rat ileum, involves, at least, NTPDase 2 and 3 along with ecto-5'-nucleotidase/
 454 CD73 [19]. This finding is functionally relevant considering that AMP precursors, such as both ATP and ADP, feed-
 455 forwardly inhibit CD73 contributing to slow down adenosine formation and, thus, to the dissociation of the effects of
 456 nucleotide-sensitive P2 receptors from adenosine-operated P1 receptors [8, 9, 19].

463 Detection of high adenosine concentrations compared to those of inosine and hypoxanthine confirms the presence of
 464 a very intense CD73 activity and a low ecto-ADA activity in IMFs cultures. The ability of IMFs to clear much higher
 465 extracellular AMP concentrations than those present in physiological conditions without showing any sign of cell damage
 466 as well as the high rate of AMP clearance and its metabolites formation in the medium is indicative for a high metabolic
 467 activity of IMFs versus the nucleotide. The kinetics of AMP catabolism in cultured IMFs was found to be significantly
 468 different from that shown in isolated LMMPs of the rat ileum
 469
 470
 471
 472
 473

[8]. Moreover, in LMMPs, the half-life of exogenously added AMP (i.e., 15.04 ± 2.42 min) was longer than in IMFs primary culture, possibly reflecting a diverse expression and/or activity of CD73 in the different cell subtypes composing the isolated ileal LMMPs. Indeed, the K_m value of $146 \mu\text{M}$ obtained with our primary culture was similar to values found in vascular smooth muscle cell cultures ($100\text{--}150 \mu\text{M}$) and arterial smooth muscle cells ($82 \mu\text{M}$) [34, 35]. Other *in vitro* studies, carried out in many different cell types, such as rat Sertoli cells [36], human intestinal epithelial cells [37], microvascular endothelial cells [38], and bronchial epithelial cells [22], showed that extracellular dephosphorylation of AMP into adenosine is primarily mediated by CD73, the so called purine rescue enzyme. This enzyme, also identified as ecto-5'-nucleotidase (ecto-5'-NT, EC 3.1.3.5) is a 70-kD glycosylphosphatidylinositol protein, anchored to the cell surface, and encoded by the NT5E gene. CD73 plays a crucial role in switching purinergic signaling from ATP-dependent to adenosine-dependent signaling cascades [8, 9, 13, 19]. In the last years, the modulation of this protein has been also suggested to represent a critical checkpoint not only in the control of tumor development but also in the severity of a variety of other diseases, including tissue fibrosis, infections, and autoimmune diseases [5, 39, 40].

Alkaline phosphatases (APs) are tissue-nonspecific enzymes, expressed on intestinal, placental, and germ cells, which contribute to the metabolism of AMP to adenosine and share many common features with CD73, such as being glycosylphosphatidylinositol (GPI)-anchored ecto-enzymes, displaying similar molecular weight and forming homomeric dimers [32, 41]. Similarly to CD73, APs can be released as soluble forms and are highly expressed in the intestines and kidneys where they are considered specific markers [41, 42]. In spite of these similarities, the contribution of APs to adenosine generation in the gastrointestinal tract has only been partially investigated until now [43]. We have thus tried to evaluate the differential contribution of CD73 and APs in modulating AMP levels in IMFs by measuring the rate of AMP catabolism and metabolite formation in the absence or presence of specific CD73 and APs inhibitors, such as AOPCP or ConA and levamisole, respectively. AOPCP, a more stable analogue of ADP, is one of the most potent available competitive inhibitors of ecto-5'-NT, and has recently been used as a lead compound for the development of new potent CD73 inhibitors [44]. ConA, a plant lectin that binds specifically to α -D-glucosyl and α -D-mannosyl residues of glycoproteins [21], has been shown to completely block the activity of CD73 without affecting APs whereas levamisole has been shown to inhibit the enzymatic activity of tissue-nonspecific, placental and intestinal APs [22]. The kinetic profiles of AMP clearance and generation of related metabolites in IMFs medium were influenced by both AOPCP or

ConA, but not by levamisole addition. These findings suggest that CD73, but not APs, is responsible for AMP-derived adenosine production in IMFs.

The ADA inhibitor EHNA increased adenosine-to-inosine ratio without altering AMP levels, revealing that extracellular inosine accumulation is mostly derived from adenosine metabolism by ecto-ADA, which is extensively expressed in mouse [45] and rat tissues and highly active in the small intestine, as previously shown in full-thickness preparations of rat ileum by our group [10] and in rat colon by Antonioli et al. [46]. The resulting inosine could be then metabolized by purine nucleoside phosphorylase (PNP; EC 2.4.2.1) to hypoxanthine and ribose-1-phosphate [47]. The concomitant inhibition of ADA and ENTs revealed that in IMFs, adenosine deamination is a more effective pathway than the dipyridamole-sensitive equilibrative nucleoside uptake system in regulating adenosine levels in the extracellular milieu, as previously shown in rat ileal preparations of LMMPs [8].

Interestingly, CD73 blockade reduced, but did not abolish AMP clearance. It is conceivable that in the enteric smooth muscle microenvironment, an ensemble of enzymes that includes, but extends beyond, CD73 and ecto-ADA may be responsible for AMP homeostasis. For example, after knocking out CD73 in mouse dorsal root ganglia and spinal neurons, adenosine generation was only partially reduced [48]. Analogously, in neurons genetically deprived of both prostatic acid phosphatase (PAP; EC 3.1.3.2) and CD73, adenosine production was reduced by 69% [48]. A possible alternative player involved in adenosine metabolism is the prostatic acid phosphatase (PAP), a tartrate-sensitive histidine acid phosphatase enzyme with two known isoforms, the secreted (sPAP) and the type-I transmembrane (TMPAP) isoform, widely expressed in human and rodent tissues [49]. We can hypothesize that besides CD73, also PAPs might be involved in regulating extracellular adenosine levels, AMP metabolism, and smooth muscle physiology in IMFs. However, this possibility merits further investigation, especially considering the importance of an efficient metabolism and recycling of extracellular AMP in gastrointestinal pathophysiology.

In line with the critical role of adenosine signaling in the intestine, here, we showed the expression of CD73 and ADA proteins in cultured IMFs. This finding suggests that surface-bound CD73 and ADA convert AMP to adenosine, which, in turn, can potentially activate P1 receptors [50].

However, a significant accumulation of adenosine was found in the incubation medium from IMFs compared to rat ileum preparations [8, 10] suggesting that ecto-ADA activity could be depressed or be less efficient in physiological conditions. These results highlight the involvement of IMFs together with other cells (e.g., interstitial cells of Cajal) located at the tripartite myenteric synapse in controlling extracellular adenosine accumulation for regulating inflammatory response [51–53].

580 Considering the potent anti-inflammatory action of adeno-
 581 sine and the ability of adenosine receptors to regulate a variety
 582 of important physiological processes [50], these data evoke
 583 important challenges for the future such as to decipher the
 584 extracellular information encoded in AMP-derived adenosine
 585 signaling and the pathophysiological implications of the ecto-
 586 enzymes responsible for its metabolism in the gut. Our results
 587 may also have potential implications for the pharmacological
 588 manipulation of endogenous adenosine content by targeting
 589 these ecto-enzymes in the enteric neuromuscular layer
 590 through the inhibition of ecto-ADA, and/or the administration
 591 of AMP-derived prodrugs able to selectively interact with P1
 592 receptor co-localized with CD73 [19]. This is still an unex-
 593 plored area, which may have beneficial effects during enteric
 594 pathogen infection, dysbiosis, motility disturbances, and im-
 595 mune reactivity inherent to inflammatory enteric disorders, or
 596 chronic inflammation-induced fibrosis [5, 28–30, 52, 53].

597 **Acknowledgments** We thank Dr. Francesca Patrese and Dr. Ludovico
 598 Scenna for veterinary assistance; Mauro Berto, Massimo Rizza, and
 599 Andrea Pagetta for technical assistance in animal handling and experi-
 600 mental procedures.

601 **Author contributions** Conceived and designed the experiments: MCG,
 602 AB, VC. Performed the experiments: AB, VC, IC, GO, MB. Analyzed
 603 the data: MCG, AB, VC, IC, GO, SDM, MM, LA, CG, RC, PD.
 604 Contributed reagents/materials/analysis tools: MCG, GO, IC, PD, CG.
 605 Wrote the manuscript: MCG, AB, VC. All the authors reviewed the
 606 manuscript.

607 **Funding information** This work was supported by grants from
 608 University of Padova (UNIPD-CPDR155591/15 Assegno di Ricerca
 609 2016, UNIPD-DSF-DOR-2016 and 2017 funds, and UNIPD-DSF-
 610 PRID-2017) and from San Camillo Hospital, Treviso (Italy) to MCG.
 611 The funders had no role in study design, data collection and analysis,
 612 decision to publish, or preparation of the manuscript.

614 Compliance with ethical standards

Q2 615 All experimental protocols were approved by the Animal Care and Use
 616 Committee of the University of Padova and by the Italian Ministry of
 617 Health and were in compliance with the national and EU guidelines for
 618 handling and use of experimental animals.

619 **Conflict of interest** The authors declare that the research was conducted
 620 in the absence of any commercial or financial relationships that could be
 621 construed as a potential conflict of interest.

Q3 622 **Ethical approval** This article does not contain any studies with human
 623 participants or animals performed by any of the authors.

624 References

- 625 1. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimi-
 Q4 626 dines. *Pharmacol Rev* 50:413–492
 627 2. Christofi FL, Zhang H, Yu JG, Guzman J, Xue J, Kim M, Wang
 628 YZ, Cooke HJ (2001) Differential gene expression of adenosine

- A1, A2a, A2b, and A3 receptors in the human enteric nervous 629
 system. *J Comp Neurol* 439:46–64 630
 3. Kolachala VL, Bajaj R, Chalasani M, Sitaraman SV (2008) 631
 Purinergic receptors in gastrointestinal inflammation. *Am J* 632
Physiol Gastrointest Liver Physiol 294(2):G401–G410. <https://doi.org/10.1152/ajpgi.00454.2007> 633
 4. Antonioli L, Colucci R, Pellegrini C, Giustarini G, Tuccori M, 634
 Blandizzi C, Fornai M (2013) The role of purinergic pathways in 635
 the pathophysiology of gut diseases: pharmacological modulation 636
 and potential therapeutic applications. *Pharmacol Ther* 139(2):157– 637
 188. <https://doi.org/10.1016/j.pharmthera.2013.04.002> 638
 5. Zoppellaro C, Bin A, Brun P, Banzato S, Macchi V, Castagliuolo I, 639
 Giron MC (2013) Adenosine-mediated enteric neuromuscular func- 640
 tion is affected during herpes simplex virus type 1 infection of rat 641
 enteric nervous system. *PLoS One* 8(8):e72648. <https://doi.org/10.1371/journal.pone.0072648> 642
 6. Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling 643
 during inflammation. *Nature* 509(7500):310–317. <https://doi.org/10.1038/nature13085> 644
 7. Nitahara K, Kittel A, Liang SD, Vizi ES (1995) A1-receptor- 645
 mediated effect of adenosine on the release of acetylcholine from 646
 the myenteric plexus: role and localization of ecto-ATPase and 5'- 647
 nucleotidase. *Neuroscience* 67(1):159–168 648
 8. Duarte-Araujo M, Nascimento C, Alexandrina Timoteo M, 649
 Magalhaes-Cardoso T, Correia-de-Sa P (2004) Dual effects of 650
 adenosine on acetylcholine release from myenteric motoneurons 651
 are mediated by junctional facilitatory A(2A) and extrajunctional 652
 inhibitory A(1) receptors. *Br J Pharmacol* 141(6):925–934. <https://doi.org/10.1038/sj.bjp.0705697> 653
 9. Correia-de-Sa P, Adaes S, Timoteo MA, Vieira C, Magalhaes- 654
 Cardoso T, Nascimento C, Duarte-Araujo M (2006) Fine-tuning 655
 modulation of myenteric motoneurons by endogenous adenosine: 656
 on the role of secreted adenosine deaminase. *Autonomic neurosci- 657*
ence: basic & clinical 126–127:211–224. [https://doi.org/10.1016/j. 658](https://doi.org/10.1016/j.autneu.2006.02.004)
 10. Giron MC, Bin A, Brun P, Etteri S, Bolego C, Florio C, Gaion RM 659
 (2008) Cyclic AMP in rat ileum: evidence for the presence of an 660
 extracellular cyclic AMP-adenosine pathway. *Gastroenterology* 661
 134(4):1116–1126. <https://doi.org/10.1053/j.gastro.2008.01.030> 662
 11. Fukuuchi T, Kobayashi M, Yamaoka N, Kaneko K (2016) 663
 Evaluation of cellular purine transport and metabolism in the 664
 Caco-2 cell using comprehensive high-performance liquid chroma- 665
 tography method for analysis of purines. *Nucleosides Nucleotides 666*
Nucleic Acids 35(10–12):663–669. [https://doi.org/10.1080/ 667](https://doi.org/10.1080/15257770.2016.1205195)
 12. Antonioli L, Pellegrini C, Fornai M, Tirota E, Gentile D, Benvenuti 668
 L, Giron MC, Caputi V, Marsilio I, Orso G, Bernardini N, Segnani 669
 C, Ippolito C, Csóka B, Németh ZH, Haskó G, Scarpignato C, 670
 Blandizzi C, Colucci R (2017) Colonic motor dysfunctions in a 671
 mouse model of high-fat diet-induced obesity: an involvement of 672
 A(2B) adenosine receptors. *Purinergic Signal* 13(4):497–510 673
 13. Duarte-Araujo M, Nascimento C, Timoteo MA, Magalhaes- 674
 Cardoso MT, Correia-de-Sa P (2009) Relative contribution of 675
 ecto-ATPase and ecto-ATPase pathways to the biphasic effect of 676
 ATP on acetylcholine release from myenteric motoneurons. *Br J 677*
Pharmacol 156(3):519–533. [https://doi.org/10.1111/j.1476-5381. 678](https://doi.org/10.1111/j.1476-5381.2008.00058.x)
 14. Antonioli L, Pacher P, Vizi ES, Haskó G (2013) CD39 and CD73 in 679
 immunity and inflammation. *Trends Mol Med* 19(6):355–367. 680
<https://doi.org/10.1016/j.molmed.2013.03.005> 681
 15. Cardoso AM, Schetinger MR, Correia-de-Sa P, Sevigny J (2015) 682
 Impact of ectonucleotidases in autonomic nervous functions. *Auton 683*
Neurosci 191:25–38. <https://doi.org/10.1016/j.autneu.2015.04.014> 684
 16. Jackson EK, Mi Z, Dubey RK (2007) The extracellular cAMP- 685
 adenosine pathway significantly contributes to the in vivo 686
 687
 688
 689
 690
 691
 692
 693

- 694 production of adenosine. *J Pharmacol Exp Ther* 320(1):117–123.
 695 <https://doi.org/10.1124/jpet.106.112748>
- 696 17. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H,
 697 Gatell JM, Gallart T, Mallol J, Lluís C, Franco R (2005) CD26,
 698 adenosine deaminase, and adenosine receptors mediate
 699 costimulatory signals in the immunological synapse. *Proc Natl*
 700 *Acad Sci U S A* 102(27):9583–9588. [https://doi.org/10.1073/](https://doi.org/10.1073/pnas.0501050102)
 701 [pnas.0501050102](https://doi.org/10.1073/pnas.0501050102)
- 702 18. Antonioli L, Colucci R, La Motta C, Tuccori M, Awwad O, Da
 703 Settimo F, Blandizzi C, Fornai M (2012) Adenosine deaminase in
 704 the modulation of immune system and its potential as a novel target
 705 for treatment of inflammatory disorders. *Curr Drug Targets* 13(6):
 706 842–862
- 707 19. Vieira C, Magalhaes-Cardoso MT, Ferreira F, Silva I, Dias AS,
 708 Pelletier J, Sevigny J, Correia-de-Sa P (2014) Feed-forward inhibi-
 709 tion of CD73 and upregulation of adenosine deaminase contribute
 710 to the loss of adenosine neuromodulation in postinflammatory ile-
 711 itis. *Mediat Inflamm* 2014:254640. [https://doi.org/10.1155/2014/](https://doi.org/10.1155/2014/254640)
 712 [254640](https://doi.org/10.1155/2014/254640)
- 713 20. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J,
 714 Eltzschig HK, Hansen KR, Thompson LF, Colgan SP (2002) Ecto-
 715 5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1
 716 mediates permeability changes in intestinal epithelia. *J Clin*
 717 *Investig* 110(7):993–1002. <https://doi.org/10.1172/jci15337>
- 718 21. Stefanovic V, Mandel P, Rosenberg A (1975) Concanavalin A in-
 719 hibition of ecto-5'-nucleotidase of intact cultured C6 glioma cells. *J*
 720 *Biol Chem* 250(17):7081–7083
- 721 22. Picher M, Burch LH, Hirsh AJ, Szychala J, Boucher RC (2003)
 722 Ecto 5'-nucleotidase and nonspecific alkaline phosphatase. Two
 723 AMP-hydrolyzing ectoenzymes with distinct roles in human air-
 724 ways. *J Biol Chem* 278(15):13468–13479. [https://doi.org/10.](https://doi.org/10.1074/jbc.M300569200)
 725 [1074/jbc.M300569200](https://doi.org/10.1074/jbc.M300569200)
- 726 23. Caputi V, Marsilio I, Filpa V, Cerantola S, Orso G, Bistoletti M,
 727 Paccagnella N, De Martin S, Montopoli M, Dall'Acqua S, Crema F,
 728 Di Gangi IM, Galuppini F, Lante I, Bogialli S, Rugge M, Debetto P,
 729 Giaroni C, Giron MC (2017) Antibiotic-induced dysbiosis of the
 730 microbiota impairs gut neuromuscular function in juvenile mice. *Br*
 731 *J Pharmacol* 174(20):3623–3639
- 732 24. Mifflin RC, Pinchuk IV, Saada JI, Powell DW (2011) Intestinal
 733 myofibroblasts: targets for stem cell therapy. *Am J Physiol*
 734 *Gastrointest Liver Physiol* 300(5):G684–G696. [https://doi.org/10.](https://doi.org/10.1152/ajpgi.00474.2010)
 735 [1152/ajpgi.00474.2010](https://doi.org/10.1152/ajpgi.00474.2010)
- 736 25. Achenbach JE, Topliff CL, Vassilev VB, Donis RO, Eskridge KM,
 737 Kelling CL (2004) Detection and quantitation of bovine respiratory
 738 syncytial virus using real-time quantitative RT-PCR and quantita-
 739 tive competitive RT-PCR assays. *J Virol Methods* 121(1):1–6.
 740 <https://doi.org/10.1016/j.jviromet.2004.05.004>
- 741 26. Qin X, Liu S, Lu Q, Zhang M, Jiang X, Hu S, Li J, Zhang C, Gao J,
 742 Zhu MS, Feil R, Li H, Chen M, Weinstein LS, Zhang Y, Zhang W
 743 (2017) Heterotrimeric G stimulatory protein alpha subunit is re-
 744 quired for intestinal smooth muscle contraction in mice. *Gastroenterology*
 745 152(5):1114–1125.e1115. [https://doi.org/10.](https://doi.org/10.1053/j.gastro.2016.12.017)
 746 [1053/j.gastro.2016.12.017](https://doi.org/10.1053/j.gastro.2016.12.017)
- 747 27. Brun P, Giron MC, Zoppellaro C, Bin A, Porzionato A, De Caro R,
 748 Barbara G, Stanghellini V, Corinaldesi R, Zaninotto G, Palù G,
 749 Gaion RM, Tonini M, De Giorgio R, Castagliuolo I (2010) Herpes
 750 simplex virus type 1 infection of the rat enteric nervous
 751 system evokes small-bowel neuromuscular abnormalities. *Gastroenterology*
 752 138(5):1790–1801. [https://doi.org/10.1053/j.](https://doi.org/10.1053/j.gastro.2010.01.036)
 753 [gastro.2010.01.036](https://doi.org/10.1053/j.gastro.2010.01.036)
- 754 28. Chen W, Lu C, Hirota C, Iacucci M, Ghosh S, Gui X (2017) Smooth
 755 muscle hyperplasia/hypertrophy is the most prominent histol-
 756 ological change in Crohn's fibrostenosing bowel strictures: a semi-
 757 quantitative analysis by using a novel histological grading scheme.
 758 *J Crohn's Colitis* 11(1):92–104. [https://doi.org/10.1093/ecco-jcc/](https://doi.org/10.1093/ecco-jcc/jjw126)
 759 [jjw126](https://doi.org/10.1093/ecco-jcc/jjw126)
29. Longhi MS, Moss A, Jiang ZG, Robson SC (2017) Purinergic
 signaling during intestinal inflammation. *J Mol Med (Berlin, Germany)*
 95(9):915–925. [https://doi.org/10.1007/s00109-017-](https://doi.org/10.1007/s00109-017-1545-1)
 1545-1
30. Severi C, Sferra R, Scirocco A, Vetuschi A, Pallotta N, Pronio A,
 Caronna R, Di Rocco G, Gaudio E, Corazzari E, Onori P (2014)
 Contribution of intestinal smooth muscle to Crohn's disease
 fibrogenesis. *Eur J Histochem* 58(4):2457. [https://doi.org/10.](https://doi.org/10.4081/ejh.2014.2457)
 4081/ejh.2014.2457
31. Porcher C, Baldo M, Henry M, Orsoni P, Jule Y, Ward SM (2002)
 Deficiency of interstitial cells of Cajal in the small intestine of
 patients with Crohn's disease. *Am J Gastroenterol* 97(1):118–125.
<https://doi.org/10.1111/j.1572-0241.2002.05430.x>
32. Yegutkin GG (2014) Enzymes involved in metabolism of extracel-
 lular nucleotides and nucleosides: functional implications and mea-
 surement of activities. *Crit Rev Biochem Mol Biol* 49(6):473–497.
<https://doi.org/10.3109/10409238.2014.953627>
33. Antonioli L, Colucci R, Pellegrini C, Giustarini G, Sacco D, Tirota
 E, Caputi V, Marsilio I, Giron MC, Németh ZH, Blandizzi C, Fornai
 M (2016) The AMPK enzyme-complex: from the regulation of
 cellular energy homeostasis to a possible new molecular target in
 the management of chronic inflammatory disorders. *Expert Opin*
 Ther Targets 20(2):179–191. [https://doi.org/10.1517/14728222.](https://doi.org/10.1517/14728222.2016.1086752)
 2016.1086752
34. Pearson JD, Carleton JS, Gordon JL (1980) Metabolism of adenine
 nucleotides by ectoenzymes of vascular endothelial and smooth-
 muscle cells in culture. *The Biochemical journal* 190(2):421–429
35. Gordon EL, Pearson JD, Dickinson ES, Moreau D, Slakey LL
 (1989) The hydrolysis of extracellular adenine nucleotides by arte-
 rial smooth muscle cells. Regulation of adenosine production at the
 cell surface. *J Biol Chem* 264(32):18986–18995
36. Casali EA, da Silva TR, Gelain DP, Kaiser GR, Battastini AM,
 Sarkis JJ, Bernard EA (2001) Ectonucleotidase activities in Sertoli
 cells from immature rats. *Braz J Med Biol Res* 34(10):1247–1256
37. Strohmeier GR, Lencer WI, Patapoff TW, Thompson LF, Carlson
 SL, Moe SJ, Carnes DK, Mrsny RJ, Madara JL (1997) Surface
 expression, polarization, and functional significance of CD73 in
 human intestinal epithelia. *J Clin Invest* 99(11):2588–2601.
<https://doi.org/10.1172/jci119447>
38. Narravula S, Lennon PF, Mueller BU, Colgan SP (2000)
 Regulation of endothelial CD73 by adenosine: paracrine pathway
 for enhanced endothelial barrier function. *J Immunol (Baltimore, Md: 1950)*
 165(9):5262–5268
39. Allard B, Longhi MS, Robson SC, Stagg J (2017) The
 ectonucleotidases CD39 and CD73: novel checkpoint inhibitor tar-
 gets. *Immunol Rev* 276(1):121–144. [https://doi.org/10.1111/immr.](https://doi.org/10.1111/immr.12528)
 12528
40. Ferrari D, Gambari R, Idzko M, Muller T, Albanesi C, Pastore S, La
 Manna G, Robson SC, Cronstein B (2016) Purinergic signaling in
 scarring. *FASEB J* 30(1):3–12. [https://doi.org/10.1096/fj.15-](https://doi.org/10.1096/fj.15-274563)
 274563
41. Jackson EK, Cheng D, Verrier JD, Janesko-Feldman K, Kochanek
 PM (2014) Interactive roles of CD73 and tissue nonspecific alkaline
 phosphatase in the renal vascular metabolism of 5'-AMP. *Am J*
 Physiol Ren Physiol 307(6):F680–F685. [https://doi.org/10.1152/](https://doi.org/10.1152/ajprenal.00312.2014)
 ajprenal.00312.2014
42. Zimmermann H, Zebisch M, Strater N (2012) Cellular function and
 molecular structure of ecto-nucleotidases. *Purinergic Signal* 8(3):
 437–502. <https://doi.org/10.1007/s11302-012-9309-4>
43. Bilski J, Mazur-Bialy A, Wojcik D, Zahradnik-Bilska J,
 Brzozowski B, Magierowski M, Mach T, Magierowska K,
 Brzozowski T (2017) The role of intestinal alkaline phosphatase
 in inflammatory disorders of gastrointestinal tract. *Mediat Inflamm*
 2017:9074601. <https://doi.org/10.1155/2017/9074601>
44. Bhattarai S, Freundlieb M, Pippel J, Meyer A, Abdelrahman A,
 Fiene A, Lee SY, Zimmermann H, Yegutkin GG, Strater N, El-

- 826 Tayeb A, Muller CE (2015) alpha, beta-Methylene-ADP (AOPCP)
 827 derivatives and analogues: development of potent and selective
 828 ecto-5'-nucleotidase (CD73) inhibitors. *J Med Chem* 58(15):
 829 6248–6263. <https://doi.org/10.1021/acs.jmedchem.5b00802>
- 830 45. Xu PA, Kellems RE (2000) Function of murine adenosine deami-
 831 nase in the gastrointestinal tract. *Biochem Biophys Res Commun*
 832 269(3):749–757. <https://doi.org/10.1006/bbrc.2000.2357>
- 833 46. Antonioli L, Fornai M, Awwad O, Giustarini G, Pellegrini C,
 834 Tuccori M, Caputi V, Qesari M, Castagliuolo I, Brun P, Giron
 835 MC, Scarpignato C, Blandizzi C, Colucci R (2014) Role of the
 836 A(2B) receptor-adenosine deaminase complex in colonic
 837 dysmotility associated with bowel inflammation in rats. *Br J*
 838 *Pharmacol* 171(5):1314–1329. <https://doi.org/10.1111/bph.12539>
- 839 47. Zamzow CR, Xiong W, Parkinson FE (2008) Adenosine produced
 840 by neurons is metabolized to hypoxanthine by astrocytes. *J*
 841 *Neurosci Res* 86(15):3447–3455. <https://doi.org/10.1002/jnr.21789>
- 842 48. Street SE, Kramer NJ, Walsh PL, Taylor-Blake B, Yadav MC, King
 843 IF, Vihko P, Wightman RM, Millan JL, Zylka MJ (2013) Tissue-
 844 nonspecific alkaline phosphatase acts redundantly with PAP and
 845 NT5E to generate adenosine in the dorsal spinal cord. *J Neurosci*
 846 33(27):11314–11322. <https://doi.org/10.1523/jneurosci.0133-13.2013>
- 847 49. Araujo CL, Quintero IB, Kipar A, Herrala AM, Pulkka AE,
 848 Saarinen L, Hautaniemi S, Vihko P (2014) Prostatic acid
 849 phosphatase is the main acid phosphatase with 5'-ectonucleotidase
 850 activity in the male mouse saliva and regulates salivation. *Am J*
 851 *Physiol Cell Physiol* 306(11):C1017–C1027. <https://doi.org/10.1152/ajpcell.00062.2014>
- 852 50. Vieira C, Ferreirinha F, Silva I, Duarte-Araujo M, Correia-de-Sa P
 853 (2011) Localization and function of adenosine receptor subtypes at
 854 the longitudinal muscle–myenteric plexus of the rat ileum. *Neurochem Int* 59(7):1043–1055. <https://doi.org/10.1016/j.neuint.2011.08.016>
- 855 51. Caputi V, Marsilio I, Cerantola S, Roozfarakh M, Lante I, Galuppini
 856 F, Rugge M, Napoli E, Giulivi C, Orso G, Giron MC (2017) Toll-
 857 like receptor 4 modulates small intestine neuromuscular function
 858 through nitrgergic and purinergic pathways. *Front Pharmacol* 8:350. <https://doi.org/10.3389/fphar.2017.00350>
- 859 52. Brun P, Gobbo S, Caputi V, Spagnol L, Schirato G, Pasqualin M,
 860 Levorato E, Palu G, Giron MC, Castagliuolo I (2015) Toll like
 861 receptor-2 regulates production of glial-derived neurotrophic fac-
 862 tors in murine intestinal smooth muscle cells. *Mol Cell Neurosci* 68:
 863 24–35. <https://doi.org/10.1016/j.mcn.2015.03.018>
- 864 53. Vieira C, Ferreirinha F, Magalhaes-Cardoso MT, Silva I, Marques P,
 865 Correia-de-Sa P (2017) Post-inflammatory ileitis induces non-
 866 neuronal purinergic signaling adjustments of cholinergic neuro-
 867 transmission in the myenteric plexus. *Front Pharmacol* 8:811. <https://doi.org/10.3389/fphar.2017.00811>
- 872 873

UNCORRECTED PROOF

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

- Q1. Figure 3 contains poor-quality text in the image, blurry image, and text below the minimum required font size of 6pts. Please provide replacement figure file.
- Q2. A statement of ethical approval is required to appear before the references for studies involving human or animal subjects. Hence, a related statement was copied from the main text and placed under “Compliance with ethical standards.” Please check if this is appropriate or amend as deemed necessary.
- Q3. “Ethical approval” section has been provided. Please check if appropriate.
- Q4. The reference list and the corresponding citations have been renumbered accordingly to ensure that they are in sequential order. Please check.

UNCORRECTED PROOF